Virpax Pharmaceuticals (NASDAQ:VRPX – Get Free Report) is anticipated to announce its resultson Tuesday, March 24th. Analysts expect the company to announce earnings of ($2.75) per share for the quarter.
Virpax Pharmaceuticals Price Performance
Virpax Pharmaceuticals stock opened at $0.00 on Monday. The stock’s 50 day moving average is $0.01 and its 200 day moving average is $0.02. Virpax Pharmaceuticals has a one year low of $0.00 and a one year high of $3.77.
About Virpax Pharmaceuticals
Virpax Pharmaceuticals, Inc (NASDAQ: VRPX) is a clinical-stage specialty pharmaceutical company dedicated to the research, development and manufacturing of vaccines and injectable therapeutics. Headquartered in Fort Lauderdale, Florida, the company leverages proprietary formulation and drug‐delivery platforms to enhance the stability, bioavailability and tolerability of its product candidates. Virpax’s integrated model spans early-stage discovery through cGMP manufacturing, enabling seamless progression from laboratory proof‐of‐concept to large-scale production.
Virpax’s pipeline encompasses a range of vaccine candidates targeting diseases such as rabies, herpes zoster and other infectious threats.
Featured Articles
Receive News & Ratings for Virpax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virpax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
